<p>Fair trade regulator CCI has cleared Kotak Special Situations Fund's (KSSF) proposed investment in Biocon Biologics Ltd under the green channel route.</p>.<p> In February, KSSF, an arm of Kotak Mahindra Bank, announced a Rs 1,070 crore investment in Biocon to help a subsidiary of the Bengaluru-based company in an acquisition.</p>.<p>The investment will help Biocon Biologics' acquisition of the biosimilars business of its partner Viatris.</p>.<p> KSSF is a Sebi-registered alternative investment fund (AIF).</p>.<p> The combination relates to the acquirer (KSSF) proposing to purchase certain equity shares in the target (Biocon Biologics).</p>.<p> Biocon Biologics is a biosimilars company which is engaged in the manufacture and commercialisation of pharmaceutical formulations.</p>.<p> The Competition Commission of India (CCI) said it has approved the deal.</p>.<p> 'The parties' activities do not exhibit any horizontal, vertical, or complementary overlaps in any of the plausible relevant markets.</p>.<p> 'Therefore, the proposed combination is being notified under the green channel,' according to an update on CCI's website on Thursday.</p>.<p> Under the green channel route, a transaction which does not raise any risk of an appreciable adverse effect on competition is deemed to be approved on being intimated to the anti-trust regulator.</p>
<p>Fair trade regulator CCI has cleared Kotak Special Situations Fund's (KSSF) proposed investment in Biocon Biologics Ltd under the green channel route.</p>.<p> In February, KSSF, an arm of Kotak Mahindra Bank, announced a Rs 1,070 crore investment in Biocon to help a subsidiary of the Bengaluru-based company in an acquisition.</p>.<p>The investment will help Biocon Biologics' acquisition of the biosimilars business of its partner Viatris.</p>.<p> KSSF is a Sebi-registered alternative investment fund (AIF).</p>.<p> The combination relates to the acquirer (KSSF) proposing to purchase certain equity shares in the target (Biocon Biologics).</p>.<p> Biocon Biologics is a biosimilars company which is engaged in the manufacture and commercialisation of pharmaceutical formulations.</p>.<p> The Competition Commission of India (CCI) said it has approved the deal.</p>.<p> 'The parties' activities do not exhibit any horizontal, vertical, or complementary overlaps in any of the plausible relevant markets.</p>.<p> 'Therefore, the proposed combination is being notified under the green channel,' according to an update on CCI's website on Thursday.</p>.<p> Under the green channel route, a transaction which does not raise any risk of an appreciable adverse effect on competition is deemed to be approved on being intimated to the anti-trust regulator.</p>